Navigation Links
FDA Accepts for Filing the Humanitarian Device Exemption Application For EMulate Therapeutics™ Hælo™ Pediatric System
Date:6/18/2019

EMulate Therapeutics, Inc., a clinical-stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, announced it has received notice that the US Food and Drug Administration (FDA) accepted for filing the EMulate Therapeutics application for Humanitarian Device Exemption (HDE) for the Hælo Pediatric system. The FDA granted the Humanitarian Use Device (HUD) designation for the Hælo Pediatric system in March 2018 to treat diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), in children.

Chris Rivera, EMulate Therapeutics President and Chief Executive Officer, made the announcement stating, “This is another important step for our company. Upon the HDE approval anticipated later this year, we will be able to begin commercialization of the Hælo Pediatric system in the US to treat DMG. Most importantly, we are on our way to providing a potential treatment for children with this aggressive and uniformly fatal condition.”

Donna Morgan Murray, Chief Regulatory Officer for EMulate, stated, “DMG, including DIPG, is an ultra-rare brain tumor that primarily effects children between the ages of 5 and 10 years of age. The median survival is less than 1 year following diagnosis. It is gratifying that we have the potential to bring this new and unique treatment to children suffering from this devastating disease.”

About EMulate Therapeutics
Headquartered in Seattle, EMulate Therapeutics is a clinical-stage therapeutic device company. EMulate has invented and patented a groundbreaking technology that utilizes precisely targeted ultra-low radiofrequency energy (ulRFE®) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-sterile, non-invasive, non-thermal, non-ionizing investigational device. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of medical conditions as well as to veterinary medicine and non-medical applications. EMulate’s initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Pre-clinical work is focused on exploring new applications in oncology. In addition, EMulate’s Voyager system for adults with glioblastoma is an investigational medical device in clinical development.

Media Relations Contact:
Dennis Kroft
dkroft(at)emulatetx.com
201-602-8354

Read the full story at https://www.prweb.com/releases/fda_accepts_for_filing_the_humanitarian_device_exemption_application_for_emulate_therapeutics_hlo_pediatric_system/prweb16385042.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. Dr. Kevin Hogan Accepts New Patients with Missing Teeth for Dental Implants in Mt. Pleasant, SC, to Support Self Improvement Month
2. Periodontist, Dr. Curry Leavitt Accepts New Patients for All-on-4® Dental Implants in Las Vegas, NV
3. Newly Appointed President of Wisdom Natural Brands® Accepts Prestigious Recognition
4. Dr. Kim Ross Recognizes Stroke Awareness Month, Accepts New Patients with Periodontal Disease Annapolis, MD
5. East LA Dental Office, Smiles LA, Now Accepts New Patients With a Special Promotion
6. New Vitae Wellness and Recovery Now Accepts Waivers for Payment
7. The Nanotechnology Startup Challenge in Cancer Accepts 28 Teams to Launch Startups from Unlicensed NIH Inventions
8. Dr. Mason Miner Now Accepts New Patients from Cortez, CO, for Minimally-Painful Infant Frenectomy Laser Treatment
9. Dr. Frederick Thurston Now Accepts New Patients From Winter Haven, FL, In Need of Dental Implants
10. Dr. Joseph Gaspari Now Accepts New Allentown, PA Patients for Dental Implants
11. Dr. Kenneth Peavy Now Accepts New Gum Disease Patients From Greensboro, NC for Laser Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2020)... ... ... ResMed Launches AirFit F30i, Its First Tube-up Full Face CPAP Mask , ... the AirFit F30i, Its First Tube-up Full Face ResMed CPAP Mask. The CPAPers who ... compact under-the-nose or traditional over-the-nose cushion styles, and even memory foam versus silicone cushion. ...
(Date:1/24/2020)... ... January 24, 2020 , ... A new study completed by ... (OLBH) achieved a 59 percent decrease in hospital onset CDI. This is double ... and Prevention. , The retrospective pre-post [study recently published in The ...
(Date:1/24/2020)... ... 2020 , ... SweetLeaf Stevia Sweetener, the world’s most trusted ... Jorge Cruise to educate consumers on losing weight through better diets with low ... fasting, that is fat burning and boosting your energy, and for reducing added ...
(Date:1/23/2020)... ... January 23, 2020 , ... A January 7 ... to get rid of them. The article quotes the president of the American Society ... are many. They can be caused by a person’s facial structure including an undefined ...
(Date:1/23/2020)... ... 23, 2020 , ... DelawareBio, a nonprofit trade organization with ... discussion on gene editing that goes beyond CRISPR technology. To be held Thursday, ... the event will provide an overview of the opportunities and challenges expected in ...
Breaking Medicine News(10 mins):
(Date:1/24/2020)... GAITHERSBURG, Md. (PRWEB) , ... January 24, 2020 ... ... cloud-based business resilience solutions, announces z/Archive, a new low-cost object storage solution using ... with a simple and inexpensive way to move older data to cloud storage, ...
(Date:1/23/2020)... ... 2020 , ... In the largest genetic sequencing study of ... risk for autism. The study also shows significant progress towards teasing apart the ... conditions which often overlap. The study results are published online January 23 in ...
(Date:1/23/2020)... ... January 23, 2020 , ... FiteBac® Cavity ... exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin ... FiteBac® Cavity Cleanser with 2% K21. Cavity cleansers are intended for cleansing ...
Breaking Medicine Technology: